Stiff Person Syndrome (Sps) is an important component in the neurobiology of [neurodegenerative[/diseases/[neurodegeneration[/diseases/[neurodegeneration[/diseases/[neurodegeneration--TEMP--/diseases)--FIX-- diseases. This page provides detailed information about its structure, function, and role in disease processes.
Stiff Person Syndrome (SPS) is a rare [autoimmune[/mechanisms/[autoimmunity[/mechanisms/[autoimmunity[/mechanisms/[autoimmunity--TEMP--/mechanisms)--FIX-- neurological disorder characterized by progressive muscle rigidity and painful spasms, primarily affecting the axial and proximal limb musculature. The condition results from [autoimmune[/mechanisms/[autoimmunity[/mechanisms/[autoimmunity[/mechanisms/[autoimmunity--TEMP--/mechanisms)--FIX---mediated impairment of inhibitory [[GABA[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling--TEMP--/mechanisms)--FIX--ergic] neurotransmission, most commonly associated with high-titer [autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies--TEMP--/mechanisms)--FIX-- against glutamic acid decarboxylase 65 ([GAD65[/proteins/[gad65-protein[/proteins/[gad65-protein[/proteins/[gad65-protein--TEMP--/proteins)--FIX--), the enzyme responsible for synthesizing the inhibitory neurotransmitter [gamma-aminobutyric acid ([GABA[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling--TEMP--/mechanisms)--FIX--) (Dalakas, 2009).
First described by Moersch and Woltman in 1956 at the Mayo Clinic as "stiff-man syndrome," SPS is now recognized as a spectrum of disorders (Stiff Person Spectrum Disorders, SPSD) that includes classic SPS, stiff-limb syndrome, progressive encephalomyelitis with rigidity and myoclonus (PERM), and paraneoplastic variants. The disease has gained significant public attention in recent years, raising awareness of this often underdiagnosed condition.
SPS is rare, with prevalence estimates ranging from 1–2 per million to 1–2 per 100,000 population, depending on the study methodology and diagnostic criteria applied (Dalakas et al., 2000). Key epidemiological features include:
- Age of onset: Typically between 30–60 years, with peak incidence in the fourth to fifth decade
- Sex distribution: Female predominance, with approximately 60–70% of patients being women
- Autoimmune associations: Strong association with other [autoimmune[/mechanisms/[autoimmunity[/mechanisms/[autoimmunity[/mechanisms/[autoimmunity--TEMP--/mechanisms)--FIX-- disorders, particularly [type 1 diabetes mellitus] (30–40% of patients), [autoimmune[/mechanisms/[autoimmunity[/mechanisms/[autoimmunity[/mechanisms/[autoimmunity--TEMP--/mechanisms)--FIX-- thyroiditis, pernicious anemia, vitiligo, and celiac disease
- Paraneoplastic association: A subset of patients (5–10%) have [autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies--TEMP--/mechanisms)--FIX-- against [amphiphysin[/proteins/[amphiphysin-protein[/proteins/[amphiphysin-protein[/proteins/[amphiphysin-protein--TEMP--/proteins)--FIX-- rather than [GAD65[/proteins/[gad65-protein[/proteins/[gad65-protein[/proteins/[gad65-protein--TEMP--/proteins)--FIX--, associated with breast cancer, small cell lung cancer, or other malignancies
- Japanese prevalence: A nationwide survey estimated 0.93 per million population in Japan (Matsui et al., 2023)
The hallmark presentation of classic SPS includes:
Progressive stiffness and rigidity of the trunk musculature, particularly the paraspinal and abdominal muscles, leading to a characteristic fixed lumbar hyperlordosis. The rigid posture gives patients a "tin soldier" appearance and can result in difficulty bending, turning, or walking.
Superimposed on the chronic rigidity, patients experience episodic painful muscle spasms triggered by:
- Unexpected or sudden stimuli (startle response)
- Emotional stress and [anxiety[/mechanisms/[anxiety-disorder[/mechanisms/[anxiety-disorder[/mechanisms/[anxiety-disorder--TEMP--/mechanisms)--FIX--
- Tactile stimulation
- Sudden movements
- Environmental noise
These spasms can be severe enough to cause falls, fractures, and joint subluxation. The spasms are electromyographically distinct from [spasticity[/mechanisms/[spasticity[/mechanisms/[spasticity[/mechanisms/[spasticity--TEMP--/mechanisms)--FIX--, showing continuous motor unit activity and co-contraction of agonist and antagonist muscles.
Progressive gait difficulty develops as the disease advances, with a characteristic slow, wide-based, cautious gait. Fear of falling due to unexpected spasms often leads to agora[phobia[/mechanisms/[psychiatric-symptoms[/mechanisms/[psychiatric-symptoms[/mechanisms/[psychiatric-symptoms--TEMP--/mechanisms)--FIX-- and significant functional limitation.
Anxiety disorders, including task-specific [phobia[/mechanisms/[psychiatric-symptoms[/mechanisms/[psychiatric-symptoms[/mechanisms/[psychiatric-symptoms--TEMP--/mechanisms)--FIX--s (crossing streets, open spaces) and generalized [anxiety[/mechanisms/[anxiety-disorder[/mechanisms/[anxiety-disorder[/mechanisms/[anxiety-disorder--TEMP--/mechanisms)--FIX--, are extremely common and may be both reactive (due to fear of spasms) and neurobiological (due to impaired [GABA[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling--TEMP--/mechanisms)--FIX--ergic tone in limbic circuits).
A variant characterized by stiffness and spasms predominantly affecting one or two limbs, often the legs, with relative sparing of the trunk. [GAD65[/proteins/[gad65-protein[/proteins/[gad65-protein[/proteins/[gad65-protein--TEMP--/proteins)--FIX-- [autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies--TEMP--/mechanisms)--FIX-- may be present at lower titers.
¶ Progressive Encephalomyelitis with Rigidity and Myoclonus (PERM)
A severe variant featuring widespread rigidity, stimulus-sensitive myoclonus, brainstem dysfunction (oculomotor abnormalities, dysphagia), autonomic instability, and encephalopathy. PERM may be associated with [glycine receptor] [autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies--TEMP--/mechanisms)--FIX-- and can be fatal if untreated.
Associated with anti-[amphiphysin[/proteins/[amphiphysin-protein[/proteins/[amphiphysin-protein[/proteins/[amphiphysin-protein--TEMP--/proteins)--FIX-- [autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies--TEMP--/mechanisms)--FIX-- and underlying malignancy. The clinical presentation may be identical to classic SPS but requires oncological investigation and treatment of the underlying tumor.
SPS results from [autoimmune[/mechanisms/[autoimmunity[/mechanisms/[autoimmunity[/mechanisms/[autoimmunity--TEMP--/mechanisms)--FIX-- attack on components of inhibitory neurotransmission, predominantly [GABA[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling--TEMP--/mechanisms)--FIX--ergic pathways:
The majority (60–80%) of SPS patients harbor high-titer [autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies--TEMP--/mechanisms)--FIX-- against [GAD65[/proteins/[gad65-protein[/proteins/[gad65-protein[/proteins/[gad65-protein--TEMP--/proteins)--FIX-- (glutamic acid decarboxylase, 65 kDa isoform). GAD catalyzes the conversion of [glutamate[/mechanisms/[glutamate-excitotoxicity[/mechanisms/[glutamate-excitotoxicity[/mechanisms/[glutamate-excitotoxicity--TEMP--/mechanisms)--FIX-- to [GABA[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling--TEMP--/mechanisms)--FIX--, the principal inhibitory neurotransmitter in the central nervous system. Anti-[GAD65[/proteins/[gad65-protein[/proteins/[gad65-protein[/proteins/[gad65-protein--TEMP--/proteins)--FIX-- [autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies--TEMP--/mechanisms)--FIX-- impair [GABA[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling--TEMP--/mechanisms)--FIX-- synthesis, leading to:
- Reduced [GABA[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling--TEMP--/mechanisms)--FIX--ergic inhibition at spinal and supraspinal levels
- Loss of reciprocal inhibition between agonist and antagonist muscle groups
- Enhanced excitatory neural activity and motor neuron hyperexcitability
Importantly, serum [GAD65[/proteins/[gad65-protein[/proteins/[gad65-protein[/proteins/[gad65-protein--TEMP--/proteins)--FIX-- antibody titers in SPS typically exceed 10,000 IU/mL, which is markedly higher than the lower titers (typically <2,000 IU/mL) seen in [type 1 diabetes] or cerebellar ataxia. However, studies have shown no consistent correlation between antibody titers and disease severity (Dalakas, 2024).
Additional autoantigens targeted in SPS spectrum disorders include:
- Amphiphysin: A presynaptic vesicle protein involved in [GABA[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling--TEMP--/mechanisms)--FIX-- release. Anti-[amphiphysin[/proteins/[amphiphysin-protein[/proteins/[amphiphysin-protein[/proteins/[amphiphysin-protein--TEMP--/proteins)--FIX-- [autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies--TEMP--/mechanisms)--FIX-- are strongly associated with paraneoplastic SPS
- Glycine receptor: A postsynaptic inhibitory receptor targeted in PERM
- Gephyrin: A tubulin-binding protein needed for clustering both [GABA[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling--TEMP--/mechanisms)--FIX---A and glycine receptors
- [GABA[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling--TEMP--/mechanisms)--FIX---A receptor-associated protein ([GABA[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling--TEMP--/mechanisms)--FIX--RAP): A linker protein for [GABA[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling--TEMP--/mechanisms)--FIX---A receptor organization
The core pathophysiological mechanism is disruption of inhibitory neurotransmission at multiple levels of the neuraxis:
- Spinal level: Loss of reciprocal and presynaptic inhibition leads to continuous motor unit activity and co-contraction of agonist-antagonist pairs
- Brainstem: Impaired inhibitory circuits controlling the startle response and autonomic function
- Cortical/limbic: Reduced [GABA[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling--TEMP--/mechanisms)--FIX--ergic tone contributes to [anxiety[/mechanisms/[anxiety-disorder[/mechanisms/[anxiety-disorder[/mechanisms/[anxiety-disorder--TEMP--/mechanisms)--FIX--, hyperexcitability, and task-specific [phobia[/mechanisms/[psychiatric-symptoms[/mechanisms/[psychiatric-symptoms[/mechanisms/[psychiatric-symptoms--TEMP--/mechanisms)--FIX--s
- Cerebellar: [GAD65[/proteins/[gad65-protein[/proteins/[gad65-protein[/proteins/[gad65-protein--TEMP--/proteins)--FIX---mediated dysfunction may cause cerebellar ataxia in a subset of patients
¶ Intrathecal Antibody Production
In many SPS patients, [GAD65[/proteins/[gad65-protein[/proteins/[gad65-protein[/proteins/[gad65-protein--TEMP--/proteins)--FIX-- [autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies--TEMP--/mechanisms)--FIX-- are produced intrathecally (within the central nervous system), as evidenced by elevated CSF/serum antibody index. This suggests that the [autoimmune[/mechanisms/[autoimmunity[/mechanisms/[autoimmunity[/mechanisms/[autoimmunity--TEMP--/mechanisms)--FIX-- process is not merely peripheral but directly involves CNS immune responses.
The modified Dalakas criteria for classic SPS diagnosis include:
- Stiffness in axial muscles (paraspinals and abdominals) leading to fixed deformity (hyperlordosis)
- Superimposed painful spasms triggered by unexpected stimuli
- Absence of other neurological findings that could explain stiffness
- Electromyographic (EMG) confirmation of continuous motor unit activity in stiff muscles
- Positive anti-[GAD65[/proteins/[gad65-protein[/proteins/[gad65-protein[/proteins/[gad65-protein--TEMP--/proteins)--FIX-- [autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies--TEMP--/mechanisms)--FIX-- (typically >10,000 IU/mL)
- Anti-[GAD65[/proteins/[gad65-protein[/proteins/[gad65-protein[/proteins/[gad65-protein--TEMP--/proteins)--FIX-- [autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies--TEMP--/mechanisms)--FIX--: Serum and CSF testing. Titers >10,000 IU/mL are highly suggestive
- Anti-[amphiphysin[/proteins/[amphiphysin-protein[/proteins/[amphiphysin-protein[/proteins/[amphiphysin-protein--TEMP--/proteins)--FIX-- [autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies--TEMP--/mechanisms)--FIX--: If [GAD65[/proteins/[gad65-protein[/proteins/[gad65-protein[/proteins/[gad65-protein--TEMP--/proteins)--FIX-- negative or cancer is suspected
- Anti-glycine receptor [autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies--TEMP--/mechanisms)--FIX--: If PERM is suspected
- CSF analysis: Oligoclonal bands may be present; intrathecal [GAD65[/proteins/[gad65-protein[/proteins/[gad65-protein[/proteins/[gad65-protein--TEMP--/proteins)--FIX-- antibody synthesis
- Cancer screening: Particularly for [amphiphysin[/proteins/[amphiphysin-protein[/proteins/[amphiphysin-protein[/proteins/[amphiphysin-protein--TEMP--/proteins)--FIX---positive patients (mammography, CT chest/abdomen/pelvis)
- Needle EMG: Continuous involuntary motor unit activity at rest in paraspinal and proximal muscles, persisting despite attempts to relax. Co-activation of agonist and antagonist muscles
- Startle reflex studies: Exaggerated startle response with prolonged muscle activity
Brain and spinal [MRI] are typically normal in classic SPS. MRI is primarily useful to exclude other causes of progressive rigidity (e.g., myelopathy, [multiple sclerosis).
- [multiple sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis[/diseases/[multiple-sclerosis--TEMP--/diseases)--FIX-- — [spasticity[/mechanisms/[spasticity[/mechanisms/[spasticity[/mechanisms/[spasticity--TEMP--/mechanisms)--FIX--, but with distinct MRI lesions
- Neuromyotonia (Isaacs syndrome) — peripheral nerve hyperexcitability
- Tetanus — acute onset, Clostridium tetani infection
- Ankylosing spondylitis — inflammatory joint disease, not neurological
- Conversion disorder/functional neurological disorder
- Dystonia — different movement pattern
- Primary lateral sclerosis — upper motor neuron signs
- Hereditary spastic paraplegia — genetic, upper motor neuron pattern
¶ Treatment and Management
- Benzodiazepines: [Diazepam] (20–100 mg/day) or clonazepam (2–6 mg/day) are the mainstay of symptomatic therapy. They enhance [GABA[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling--TEMP--/mechanisms)--FIX---A receptor function, reducing both rigidity and spasm frequency. High doses are often required, and tolerance may develop
- Baclofen: A [GABA[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling--TEMP--/mechanisms)--FIX---B receptor agonist, used orally (40–100 mg/day) or via intrathecal pump for refractory cases. Intrathecal baclofen can be dramatically effective when oral medications fail
- Other agents: Gabapentin, pregabalin, tizanidine, and dantrolene may provide additional benefit
IVIg is the best-studied [immunotherapy[/treatments/[immunotherapy[/treatments/[immunotherapy[/treatments/[immunotherapy--TEMP--/treatments)--FIX-- for SPS. A landmark double-blind, placebo-controlled crossover trial by Dalakas et al. (2001) demonstrated significant improvement in stiffness and heightened sensitivity scores. IVIg is typically administered at 2 g/kg over 2–5 days, repeated every 4–8 weeks (Dalakas et al., 2001).
Anti-CD20 [B-cell depleting therapy[/treatments/[[immunotherapy[/treatments/[immunotherapy[/treatments/[[immunotherapy--TEMP--/treatments/immunotherapy[//treatments//treatments/[immunotherapy--TEMP--//treatments//treatments/[immunotherapy[//treatments//treatments//treatments/[immunotherapy--TEMP--//treatments//treatments/[immunotherapy[//treatments//treatments//treatments/[immunotherapy](//treatments//treatments/immunotherapy](//treatments//treatments/[immunotherapy](//treatments//treatments//treatments/immunotherapy](//treatments//treatments/[immunotherapy](/treatments//treatments//treatments//treatments/immunotherapy](//treatments//treatments//treatments/immunotherapy](//treatments//treatments/immunotherapy](//treatments//treatments/[immunotherapy](//treatments//treatments//treatments/immunotherapy](//treatments//treatments/immunotherapy (//treatments//treatments)--FIX-- (/treatments//treatments/immunotherapy) ()--FIX-- (/treatments/immunotherapy) ()--FIX--) has shown promise in case series and small studies, particularly in patients refractory to IVIg. A systematic review found that rituximab may reduce disease activity and improve mobility, though effects on rigidity and pain are variable (Diaz-Manera et al., 2025). However, a controlled trial showed no significant benefit on the primary endpoint.
Plasma exchange can provide rapid but temporary improvement by removing circulating [autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies--TEMP--/mechanisms)--FIX--. Typically used as rescue therapy during severe exacerbations.
¶ Corticosteroids and Other Immunosuppressants
Azathioprine, mycophenolate mofetil, and corticosteroids have been used with variable results. Evidence is limited to case reports and small series.
In paraneoplastic cases, treatment of the underlying malignancy is essential and may improve neurological symptoms. Immunotherapy is used concurrently.
Physical therapy focusing on stretching, range of motion, and functional mobility is an important adjunct. Aquatic therapy may be particularly beneficial. Psychological support and cognitive behavioral therapy can help address [anxiety[/mechanisms/[anxiety-disorder[/mechanisms/[anxiety-disorder[/mechanisms/[anxiety-disorder--TEMP--/mechanisms)--FIX-- and [phobia[/mechanisms/[psychiatric-symptoms[/mechanisms/[psychiatric-symptoms[/mechanisms/[psychiatric-symptoms--TEMP--/mechanisms)--FIX--s.
The natural history of SPS is one of slow, progressive disability over years to decades:
- Without treatment, most patients develop significant ambulatory difficulty within 5–10 years
- Falls and fractures are common complications
- Quality of life is markedly impaired by pain, rigidity, and [anxiety[/mechanisms/[anxiety-disorder[/mechanisms/[anxiety-disorder[/mechanisms/[anxiety-disorder--TEMP--/mechanisms)--FIX--
- With appropriate symptomatic and immunomodulatory therapy, many patients maintain functional independence for extended periods
- Paraneoplastic SPS may have a worse prognosis, depending on the underlying malignancy
- PERM variant carries a more guarded prognosis with higher mortality if untreated
SPS does not directly cause neurodegeneration in the traditional sense (i.e., progressive neuronal loss), but chronic [GABA[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling--TEMP--/mechanisms)--FIX--ergic dysfunction may lead to excitotoxic neuronal injury via excessive [glutamate[/mechanisms/[glutamate-excitotoxicity[/mechanisms/[glutamate-excitotoxicity[/mechanisms/[glutamate-excitotoxicity--TEMP--/mechanisms)--FIX-- signaling and [excitotoxicity[/entities/[excitotoxicity[/entities/[excitotoxicity[/entities/[excitotoxicity--TEMP--/entities)--FIX--.
Research continues to elucidate whether [GAD65[/proteins/[gad65-protein[/proteins/[gad65-protein[/proteins/[gad65-protein--TEMP--/proteins)--FIX-- [autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies--TEMP--/mechanisms)--FIX-- are directly pathogenic or serve as biomarkers for a broader T cell-mediated [autoimmune[/mechanisms/[autoimmunity[/mechanisms/[autoimmunity[/mechanisms/[autoimmunity--TEMP--/mechanisms)--FIX-- process. The lack of correlation between antibody titers and clinical severity suggests that cellular immunity plays a critical role (Dalakas, 2024).
- Anti-CD19 therapy: Targeting a broader B-cell population than rituximab
- Anti-BAFF agents: Blocking B-cell survival factor
- Complement inhibitors: Targeting complement-mediated neural injury
- IL-6 receptor blockade: Tocilizumab has shown promise in case reports
- CAR-T cell therapy: Theoretical application for refractory [autoimmune[/mechanisms/[autoimmunity[/mechanisms/[autoimmunity[/mechanisms/[autoimmunity--TEMP--/mechanisms)--FIX-- disease
- Standardized outcome measures and clinical scales for SPS are being developed to enable better clinical trial design
- CSF biomarkers beyond [GAD65[/proteins/[gad65-protein[/proteins/[gad65-protein[/proteins/[gad65-protein--TEMP--/proteins)--FIX-- [autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies--TEMP--/mechanisms)--FIX-- are being explored
- Advanced [neuroimaging[/diagnostics/[neuroimaging[/diagnostics/[neuroimaging[/diagnostics/[neuroimaging--TEMP--/diagnostics)--FIX-- techniques including functional MRI and MR spectroscopy may reveal subtle changes in [GABA[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling[/mechanisms/[gaba-signaling--TEMP--/mechanisms)--FIX--ergic circuitry
The concept of Stiff Person Spectrum Disorders continues to evolve, with improved understanding of the immunological and clinical heterogeneity across the spectrum. Identifying antibody profiles that predict treatment response remains an active area of investigation (Graus et al., 2023).
- [Immunotherapy for Neurodegenerative Diseases[/treatments/[[immunotherapy[/treatments/[immunotherapy[/treatments/[[immunotherapy--TEMP--/treatments/immunotherapy[//treatments//treatments/[immunotherapy--TEMP--//treatments//treatments/[immunotherapy[//treatments//treatments//treatments/[immunotherapy--TEMP--//treatments//treatments/[immunotherapy[//treatments//treatments//treatments/[immunotherapy](//treatments//treatments/immunotherapy](//treatments//treatments/[immunotherapy](//treatments//treatments//treatments/immunotherapy](//treatments//treatments/[immunotherapy](/treatments//treatments//treatments//treatments/immunotherapy](//treatments//treatments//treatments/immunotherapy](//treatments//treatments/immunotherapy](//treatments//treatments/[immunotherapy](//treatments//treatments//treatments/immunotherapy](//treatments//treatments/immunotherapy (//treatments//treatments)--FIX-- (/treatments//treatments/immunotherapy) ()--FIX-- (/treatments/immunotherapy) ()--FIX--)
The study of Stiff Person Syndrome (Sps) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Moersch FP, Woltman HW. Progressive fluctuating muscular rigidity and spasm ("stiff-man" syndrome]: report of a case and some observations in 13 other cases. Proc Staff Meet Mayo Clin. 1956;31(15):421-427.
- Solimena M, Folli F, Denis-Donini S, et al. Auto[autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies[/mechanisms/[autoantibodies--TEMP--/mechanisms)--FIX-- to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med. 1988;318(16]:1012-1020.
- [Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B. High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med. 2001;345(26]:1870-1876. NEJM)
- Dalakas MC. Stiff person syndrome: advances in pathogenesis and therapeutic interventions. Curr Treat Options Neurol. 2009;11(2]:102-110.
- [Dalakas MC. Therapies in stiff-person syndrome: advances and future prospects based on disease pathophysiology. Neurol Neuroimmunol Neuroinflamm. 2023;10(4]:e200109. Neurology)
- [Dalakas MC. Therapies in stiff-person syndrome. Neurol Neuroimmunol Neuroinflamm. 2024;10:e200109. PMC)
- [Matsui N, et al. Prevalence, clinical profiles, and prognosis of stiff-person syndrome in a Japanese nationwide survey. Neurol Neuroimmunol Neuroinflamm. 2023;10(5]:e200165. Neurology)
- [Graus F, et al. Stiff person spectrum disorders—an update and outlook on clinical, pathophysiological and treatment perspectives. Biomedicines. 2023;11(9]:2500. MDPI)
- [Diaz-Manera J, et al. Rituximab in stiff-person syndrome with glutamic acid decarboxylase 65 autoantibody: a systematic review. J Neurol. 2025;272:222. Springer)
- Alexopoulos H, Dalakas MC. The immunobiology of [autoimmune[/mechanisms/[autoimmunity[/mechanisms/[autoimmunity[/mechanisms/[autoimmunity--TEMP--/mechanisms)--FIX-- encephalitides. J Autoimmun. 2019;104:102339.
- Hadavi S, Noyce AJ, Leslie RD, Giovannoni G. Stiff person syndrome. Pract Neurol. 2011;11(5]:272-282.
- McKeon A, Robinson MT, McEvoy KM, et al. Stiff-man syndrome and variants: clinical course, treatments, and outcomes. Arch Neurol. 2012;69(2]:230-238.
- [StatPearls. Stiff Person Syndrome. StatPearls)
- Baizabal-Carvallo JF, Jankovic J. Stiff-person syndrome: insights into a complex [autoimmune[/mechanisms/[autoimmunity[/mechanisms/[autoimmunity[/mechanisms/[autoimmunity--TEMP--/mechanisms)--FIX-- disorder. J Neurol Neurosurg Psychiatry. 2015;86(8]:840-848.